The U.S. Food and Drug Administration (FDA) has approved extended-release injectable suspension of risperidone (UZEDY, Teva) for the treatment of schizophrenia in adults.
This new approval is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone. Therapeutic blood concentrations are reached within 6-24 hours of a single dose. It utilizaes this copolymer technology to slowly release the active ingredient, risperidone, over a period of one to two months.
The approval was based on data data from two phase 3 trials: Risperidone Subcutaneous Extended-Release Study, or the RISE study, and the Study to Test TV-46000 for Maintenance Treatment of Schizophrenia, or the SHINE Study. Both studies showed the drug is well tolerated with a good safety profile and can reduce relapse in schizophrenia by up to 80 percent.
>> Teva and MedinCell Press Release
For more information:
Episode 135 - (CME) The Art of Switching Antipsychotics to Better Treat Patients with Schizophrenia
CME/CE credits: 1.00 | Expires: January 26, 2025
Early Use of LAI Antipsychotics for Patient Adherence, Relapse Prevention, and Brain Preservation
CME/CE credits: 0.75 | Expires: November 6, 2025
Jeopardy! Long-Acting Injectables
CME/CE credits: 0.50 | Expires: April 24, 2025
Pragmatic Precision Psychiatry: Utilizing Pharmacokinetics and Pharmacodynamics to Optimize Antipsychotic Treatment
CME/CE credits: 0.75 | Expires: November 3, 2025
Practical Guide for Converting to a Long-Acting Injectable Antipsychotic
CME/CE credits: 0.50 | Expires: April 26, 2025
Tipping the Scales: Overcoming Antipsychotic Side Effects to Improve Treatment Adherence
CME/CE credits: 1.00 | Expires: November 6, 2025
Learn about NEI Membership benefits